10-Q quarterly report · filed Nov 16, 2026

Greenwich LifeSciences, Inc. (GLSI) Q3 2026 10-Q Quarterly Report

Short answer

Greenwich LifeSciences, Inc. (GLSI) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$6M
−40.0% YoY · −47.2% QoQ
EPS (diluted)
−$0.40
−33.3% YoY · −53.8% QoQ

Source: XBRL data from the Greenwich LifeSciences, Inc. (GLSI) Q3 2026 10-Q on SEC EDGAR. USD.

Greenwich LifeSciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no commercialization achieved
  • R&D expenses $5.45M, up 67% from $3.27M, driven by clinical expenses
  • G&A expenses $412,695, down 12% from $466,926, following option-grant expirations
  • Cash $5.90M vs $6.18M at December 31, 2025, operating cash use $9.62M
  • ATM financing net proceeds $9.34M, with 379,762 shares sold at $25.36 average price; additional capital required as losses continue

Risk Factors

  • No material changes from Form 10-K risk factors for year ended December 31, 2025

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Greenwich LifeSciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.